Sentry LLC Has $491,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sentry LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 944 shares of the medical research company’s stock after selling 21 shares during the period. Sentry LLC’s holdings in Thermo Fisher Scientific were worth $491,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in TMO. Quarry LP lifted its position in Thermo Fisher Scientific by 86.2% during the 2nd quarter. Quarry LP now owns 121 shares of the medical research company’s stock worth $67,000 after acquiring an additional 56 shares during the last quarter. Advisory Alpha LLC boosted its stake in Thermo Fisher Scientific by 34.7% during the 2nd quarter. Advisory Alpha LLC now owns 1,049 shares of the medical research company’s stock valued at $580,000 after purchasing an additional 270 shares during the period. 3Chopt Investment Partners LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $401,000. Founders Financial Alliance LLC boosted its position in shares of Thermo Fisher Scientific by 33.6% in the second quarter. Founders Financial Alliance LLC now owns 477 shares of the medical research company’s stock valued at $264,000 after acquiring an additional 120 shares during the period. Finally, Brown Financial Advisors acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $671,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TMO shares. Barclays decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Stifel Nicolaus lowered their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley decreased their price objective on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Bank of America reduced their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Bernstein Bank boosted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total value of $5,581,200.00. Following the transaction, the chief executive officer now owns 33,608 shares of the company’s stock, valued at $18,757,296.96. This represents a 22.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 34,850 shares of company stock worth $19,123,197 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 2.9 %

TMO opened at $567.09 on Thursday. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The firm has a 50-day moving average price of $536.74 and a two-hundred day moving average price of $570.35. The stock has a market capitalization of $216.91 billion, a PE ratio of 35.55, a PEG ratio of 3.82 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.